Cargando…

Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization

Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Manali, Brettmann, Blair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589131/
https://www.ncbi.nlm.nih.gov/pubmed/33092148
http://dx.doi.org/10.3390/pharmaceutics12100995
_version_ 1783600508021243904
author Banerjee, Manali
Brettmann, Blair
author_facet Banerjee, Manali
Brettmann, Blair
author_sort Banerjee, Manali
collection PubMed
description Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal size and habit further contribute to this variability. An important focus in pharmaceutical research has been on controlling the drug form to improve the solubility and thus bioavailability of APIs. In this regard, heterogeneous crystallization on surfaces and crystallization under confinement have become prominent forms of controlling polymorphism and drug crystal size and habits; however there has not been a thorough review into the emerging field of combining these approaches to control crystallization. This tutorial-style review addresses the major advances that have been made in controlling API forms using combined crystallization methods. By designing templates that not only control the surface functionality but also enable confinement of particles within a porous structure, these combined systems have the potential to provide better control over drug polymorph formation and crystal size and habit. This review further provides a perspective on the future of using a combined crystallization approach and suggests that combining surface templating with confinement provides the advantage of both techniques to rationally design systems for API nucleation.
format Online
Article
Text
id pubmed-7589131
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75891312020-10-29 Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization Banerjee, Manali Brettmann, Blair Pharmaceutics Review Poor water solubility is one of the major challenges to the development of oral dosage forms containing active pharmaceutical ingredients (APIs). Polymorphism in APIs leads to crystals with different surface wettabilities and free energies, which can lead to different dissolution properties. Crystal size and habit further contribute to this variability. An important focus in pharmaceutical research has been on controlling the drug form to improve the solubility and thus bioavailability of APIs. In this regard, heterogeneous crystallization on surfaces and crystallization under confinement have become prominent forms of controlling polymorphism and drug crystal size and habits; however there has not been a thorough review into the emerging field of combining these approaches to control crystallization. This tutorial-style review addresses the major advances that have been made in controlling API forms using combined crystallization methods. By designing templates that not only control the surface functionality but also enable confinement of particles within a porous structure, these combined systems have the potential to provide better control over drug polymorph formation and crystal size and habit. This review further provides a perspective on the future of using a combined crystallization approach and suggests that combining surface templating with confinement provides the advantage of both techniques to rationally design systems for API nucleation. MDPI 2020-10-20 /pmc/articles/PMC7589131/ /pubmed/33092148 http://dx.doi.org/10.3390/pharmaceutics12100995 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Banerjee, Manali
Brettmann, Blair
Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
title Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
title_full Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
title_fullStr Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
title_full_unstemmed Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
title_short Combining Surface Templating and Confinement for Controlling Pharmaceutical Crystallization
title_sort combining surface templating and confinement for controlling pharmaceutical crystallization
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589131/
https://www.ncbi.nlm.nih.gov/pubmed/33092148
http://dx.doi.org/10.3390/pharmaceutics12100995
work_keys_str_mv AT banerjeemanali combiningsurfacetemplatingandconfinementforcontrollingpharmaceuticalcrystallization
AT brettmannblair combiningsurfacetemplatingandconfinementforcontrollingpharmaceuticalcrystallization